RBPJ inhibits the movability of endometrial carcinoma cells by miR-155/NF-κB/ROS pathway

Yufeng Xiao; Xiaoli Wang; Xiping Dong; Yan Zhang; Haibin Liu

doi:10.2147/OTT.S212519

RBPJ inhibits the movability of endometrial carcinoma cells by miR-155/NF-κB/ROS pathway

Onco Targets Ther. 2019 Oct 2:12:8075-8084. doi: 10.2147/OTT.S212519. eCollection 2019.

Authors

Yufeng Xiao^#¹, Xiaoli Wang^#², Xiping Dong³, Yan Zhang¹, Haibin Liu⁴

Affiliations

¹ Department of Gynecology, Chengwu People's Hospital, Heze, Shandong Province 274700, People's Republic of China.
² Department of Gynecology, Liangshan People's Hospital, Jining, Shandong Province 272699, People's Republic of China.
³ Department of Obstetrics and Gynecology, The First People's Hospital of Ji'nan, Ji'nan, Shandong Province 250011, People's Republic of China.
⁴ Department of Gynecology and Obstetrics, Heze Municipal Hospital, Heze, Shandong Province 274000, People's Republic of China.

^# Contributed equally.

Abstract

Background: Recombination signal-binding protein J (RBPJ) is a crucial downstream effector of Notch signaling, which is involved cell proliferation, differentiation, and apoptosis. It plays an important role in tumorigenesis although the further studies and concrete evidence are still needed. Especially for endometrial carcinoma, the functions and mechanism of RBPJ are still elusive.

Methods: The RNA expressions of RBPJ, miR-155, NF-κB, TNF-α and κB-Ras1 were examined by rt-PCR, and their protein levels were determined by Western Blot. Their expressions were inhibited by transient transfection of related siRNAs. Wound healing and transwell invasion assays were performed in ECC003 cells for measuring the migration and invasion ability, respectively. The ROS levels were detected by flow cytometry with H2DCFDA.

Purpose: This study was designed to investigate biological characteristics and molecular pathway of RBPJ in endometrial carcinoma cells, which may provide a potential therapeutic target for the treatments against endometrial carcinoma.

Results: It was shown in our study that the expression levels of RBPJ were significantly downregulated in different endometrial carcinoma cell lines. And a siRNA-mediated reduction of RBPJ enhanced the migration and invasion ability of ECC003 obviously. Besides, the results showed that the reactive oxygen species (ROS) levels increase when inhibiting RBPJ. To investigate the molecular pathway of RBPJ, we examined the expression of nuclear factor-κB (NF-κB), NF-κB inhibitor interacting Ras-like protein 1 (κB-Ras1), tumor necrosis factor-α (TNF-α) and miR-155. The results suggested that the expression of NF-κB and TNF-α significantly was promoted, while κB-Ras1 was inhibited. An upregulated expression was observed with miR-155 as well, which suggested the inhibition of NF-κB signal pathway was mediated by miR-155. Our results of Notch intracellular domain (NICD) knockdown also demonstrated that NICD is required for the inhibition of RBPJ on miR-155. And knockdown of miR-155 could inhibit the mobility of endometrial carcinoma cells.

Conclusion: Our study suggested that RBPJ can inhibit the movability of endometrial carcinoma cells by miR-155/NF-κB/ROS pathway.

Keywords: NF-κB signal; RBPJ; ROS; endometrial carcinoma; miR-155.